Weisi Medical released its 2026 interim report. Operating revenue was 226 million yuan, up 7.6% year on year. Net profit attributable to the parent was 100 million yuan, up 44.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 67.04 million yuan, up 5.5% year on year. Net operating cash flow was 59.26 million yuan, down 8.5% year on year. Fully diluted earnings per share was 1.05 yuan. In the second quarter, operating revenue was 120 million yuan, up 5.1% year on year. Net profit attributable to the parent was 38.55 million yuan, up 6.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 33.98 million yuan, up 2.9% year on year. Earnings per share was 0.4025 yuan. As of the end of the second quarter, total assets were 1.794 billion yuan, down 6.02% from the end of the previous year. Net assets attributable to the parent were 1.691 billion yuan, down 0.1% from the end of the previous year. The company continues to enrich its products and solutions in the rehabilitation medicine field, mainly covering pelvic floor and postpartum rehabilitation, mental and psychological rehabilitation, neurological rehabilitation, and pediatric rehabilitation, while actively expanding into medical aesthetics with optoelectronic devices and urology, and plans to extend its product portfolio to international markets.
Nanjing Vishee Medical Technology Co LtdFirst-half net profit attributable to parent up 44.4% year on year, beating revenue growth.
